5810-56-0

Basic information

• Product Name: 4-ACETAMIDOPIPERIDINE
• Synonyms: N-PIPERIDIN-4-YL-ACETAMIDE;4-ACETAMIDOPIPERIDINE;4-Acetylamino-piperidine;4-ACETYLAMINO-PIPERIDINE >98%;4-(N-Ethanoylamino)piperidine
• CAS NO: 5810-56-0
• Molecular Formula: C₇H₁₄N₂O
• Molecular Weight: 142.2
• Product Categories: Piperidine
• Mol File: 5810-56-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 141 °C
• Boiling Point: 318.5 °C at 760 mmHg
• Flash Point: 149.6 °C
• Appearance: /
• Density: 1.02
• Vapor Pressure: 0.000361mmHg at 25°C
• Refractive Index: 1.484
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: soluble in Methanol
• PKA: 15.96±0.20(Predicted)
• CAS DataBase Reference: 4-ACETAMIDOPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ACETAMIDOPIPERIDINE(5810-56-0)
• EPA Substance Registry System: 4-ACETAMIDOPIPERIDINE(5810-56-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 36/37/39-37-26
• Hazardous Substances Data: 5810-56-0(Hazardous Substances Data)

Usage

General Description

4-Acetamidopiperidine is a chemical compound often utilized in pharmaceutical applications and research. It is categorized as an organic compound that consists of a piperidine ring, which refers to a heterocyclic organic compound, substituted by an acetamido group. An acetamido group is a functional group consisting of a carbonyl group linked to a nitrogen atom. The molecular formula of 4-Acetamidopiperidine is C7H14N2O. Commonly, it is used as an intermediate in organic synthesis, particularly in situations where a chemist wishes to install a piperidine ring into a molecule. This substance can pose risks if improperly handled, potentially causing skin and eye irritation, and may be harmful if swallowed or inhaled.

InChI:InChI=1/C7H14N2O/c1-6(10)9-7-2-4-8-5-3-7/h7-8H,2-5H2,1H3,(H,9,10)

Upstream product

• 50534-23-1 4-acetylamino-1-benzylpiperidine 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 1093759-67-1 tert-butyl 4-acetamidopiperidine-1-carboxylate 

Downstream Products

• 141529-03-5 1-(2,2-diphenylethyl)-4-acetamidopiperidine 
• 179020-24-7 N-[1-[2-[4-(phenylmethyl)phenoxy]ethyl]piperidin-4-yl]acetamide 
• 140945-21-7 1-(2,2-diphenylethyl)-4-aminopiperidine 
• 141528-58-7 4-<<4,6-bis(allylamino)-1,3,5-triazin-2-yl>amino>-1-(2,2-diphenylethyl)piperidine 
• 141528-59-8 N-Allyl-N'-[1-(2,2-diphenyl-ethyl)-piperidin-4-yl]-N''-propyl-[1,3,5]triazine-2,4,6-triamine 
• 208179-77-5 N-ethoxycarbonylpiperidine-4-carboxyamide 
• 140945-01-3 S 9788 
• 1021531-55-4 C₃₂H₃₂F₃N₅O₃ 
• 1360586-73-7 3-(4-acetamidopiperidin-1-yl)-N-(2-((2,4-dichloro-3-(((2-methoxy-1-(pyridin-2-ylmethyl)-1H-benzo[d]imidazol-4-yl)oxy)methyl)phenyl)(methyl)amino)-2-oxoethyl)propanamide 

Relevant articles and documents

Route selection and process development of a multikilogram route to the inhaled A2a agonist UK-432,097

This article describes the selection, process development, and scale-up of a synthetic route to a complex nucleoside analogue, the A2a agonist UK-432,097 (1), that culminated in the manufacture of over 25 kg of the API. The key steps in the process were (1) a stereoselective glycosidation reaction; (2) a scalable bleach-TEMPO oxidation; and (3) an unusual elevated temperature crystallization process for the final API. The problems that were encountered with the scale-up of the route together with how they were overcome are also presented.

Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl] piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An allosteric muscarinic M 1 receptor agonist with unprecedented selectivity and procognitive potential

The discovery and Structure-activity relationship (SAR) of a series of allosteric muscarinic M1 receptor agonists are described. Compound 17 (Lu AE51090) was identified as a representative compound from the series, based on its high selectivity as an agonist at the muscarinic M1 receptor across a panel of muscarinic receptor subtypes. Furthermore, 17 displayed a high degree of selectivity when tested in a broad panel of G-protein-coupled receptors, ion channels, transporters, and enzymes, and 17 showed an acceptable pharmacokinetic profile and sufficient brain exposure in rodents in order to characterize the compound in vivo. Hence, in a rodent model of learning and memory, 17 reversed delay-induced natural forgetting, suggesting a procognitive potential of 17.

Rifamycin analogs and uses thereof

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′- and/or 6′ halo and/or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.